Darmstadt, Germany and Puteaux, France, April 19, 2018 – R-Biopharm, a globally active life science company, and ELITechGroup, a leading company in sample-to-result molecular diagnostics, announced today a worldwide agreement to strengthen their positions in molecular infectious disease testing. Under this agreement, R-Biopharm and ELITechGroup will cooperate in the development, production and marketing of real-time PCR reagents.
“Collaborating with ELITechGroup will leverage and strengthen the position of R-Biopharm in the field of molecular diagnostics”, stated Ralf Dreher, CEO of R-Biopharm. “As molecular diagnostics is one key pillar within the cross divisional strategy in the R-Biopharm Group, we are confident that this partnership will contribute significantly towards the overall success of the company.”
“We are very pleased to have won R-Biopharm as a partner to expand our molecular diagnostics portfolio”, said Christoph Gauer, CEO of ELITechGroup. “This collaboration will contribute to complete the menu of our sample-to-result system ELITe InGenius®. We will increase the overall number of CE-IVD assays from currently 23 to 33 by the end of 2018 making ELITe InGenius® the system with the broadest CE-IVD menu on the market”.
About R-Biopharm
R-Biopharm AG (Darmstadt, Germany) is a globally active life science company and a leading provider of reliable test systems for clinical diagnostics, companion diagnostics and for analyzing human food and animal feedstuffs.
Since 1988, R-Biopharm has been developing innovative products characterized by top quality, reliability and efficiency. A strong sense of responsibility, long-standing experience and a network of more than 20 affiliated companies and subsidiaries in Europe, the US, Brazil, Latin America, China, India and Australia, as well as more than 120 distribution partners, make R-Biopharm a prime partner for clients from retail, industry and public institutions looking for answers and solutions for current diagnostic and analytical challenges.
For more information contact R-Biopharm AG (info@r-biopharm.de) or visit our website: www.r-biopharm.com.
About ELITechGroup
ELITechGroup, headquartered in Paris, is a global leader in targeted segments of the In Vitro Diagnostics (IVD) market. With R&D and manufacturing facilities in Europe as well as the United States, ELITechGroup focuses on specific segments in clinical chemistry and microbiology and has a strong presence in molecular diagnostics. The company has a broad array of proven PCR assays currently in use across the world for in vitro diagnostic analysis on open systems. These assays take advantage of ELITechGroup’ s intellectual property portfolio which includes the Minor Groove Binder (MGB), modified bases, and novel fluorophores. Recently, ELITechGroup launched ELITe Ingenius®, a sample-to-result molecular diagnostics system.
About ELITe InGenius®
ELITe InGenius is the first sample-to-result solution introduced with a quantitative CE-IVD core menu for transplant pathogen monitoring. ELITe InGenius is an ease-of-use and highly flexible solution integrating all the steps of molecular diagnostics: extraction, amplification and result interpretation, in a single platform with best-in-class and proven technologies for nucleic acid extraction and RT-PCR amplification. Built on ELITechGroup expertise to design, optimize and provide efficient PCR solutions for in vitro diagnostic laboratories, the system was CE-IVD marked for IVD applications in Europe in August 2015 and is also available in the US as Laboratory Use Equipment.
For more information contact ELITechGroup (info@elitechgroup.com) or visit our website: www.elitechgroup.com.
